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BACKGROUND: MicroRNAs (miRNAs) are small non-coding RNAs, which regulate mRNA translation/decay, and may serve as
biomarkers. We characterised the expression of miRNAs in clinically sampled oral and pharyngeal squamous cell carcinoma (OSCC
and PSCC) and described the influence of human papilloma virus (HPV).
METHODS: Biopsies obtained from 51 patients with OSCC/PSCC and 40 control patients were used for microarray analysis.
The results were correlated to clinical data and HPV status. Supervised learning by support vector machines was employed to
generate a diagnostic miRNA signature.
RESULTS: One hundred and fourteen miRNAs were differentially expressed between OSCC and normal oral epithelium, with the
downregulation of miR-375 and upregulation of miR-31 as the most significant aberrations. Pharyngeal squamous cell carcinoma
exhibited 38 differentially expressed miRNAs compared with normal pharyngeal epithelium. Differences in the miRNA expression
pattern of both normal epithelium and SCC were observed between the oral cavity compared with the pharynx. Human papilloma
virus infection revealed perturbations of 21 miRNAs, most significantly in miR-127-3p and miR363. A molecular classifier including
61 miRNAs was generated for OSCC with an accuracy of 93%.
CONCLUSION: MicroRNAs may serve as useful biomarkers in OSCC and PSCC. The influence of HPV on miRNA may provide
a mechanism for the distinct clinical behaviour of HPV-infected tumours.
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Head and neck cancer is the fourth most common cancer among
men in The European Union (Black et al, 1997) and more than
21000 patients die from cancer in the oral cavity and pharynx in
the European Union each year (Bosetti et al, 2008). Squamous cell
carcinoma of the head and neck (HNSCC) is a heterogeneous
disease involving multiple anatomical localisations. Alcohol and
tobacco are predisposing factors for developing HNSCC, but
human papilloma virus (HPV) infection is also known to be
associated with HNSCC, especially squamous cell carcinoma (SCC)
of the oropharynx (tonsils). Human papilloma virus-positive
tumours have distinct clinical and prognostic features, and
discussions concerning whether or not patients with HPV-positive
tumours should be regarded as a separate group and receive
different treatment compared with HPV-negative tumours are
ongoing. Finally, problems still remain in identifying HPV and
showing the true effect of HPV in the complex environment of
other competing oncogenic factors such as alcohol and tobacco.
In general, about half of the patients with HNSCC are cured. The
clinical features as well as prognosis and treatment vary not only
with HPV status, but also with different anatomical localisations
and stage. For oral cavity SCC (OSCC), treatment comprises
excision of the primary tumour followed by sentinel node biopsy
or selective neck dissection (Bilde et al, 2006). Post-operative
radiotherapy is indicated for advanced stages or in the case of a
non-radical excision with regard to primary tumour or extra nodal
cancer growth of the regional lymph nodes. For pharyngeal (PSCC)
and laryngeal SCC, treatment is primarily radiotherapy with and
without concomitant chemotherapy. All treatment modalities are
accompanied by considerable side effects, which may have a major
impact on the quality of life in these patients. In addition, even
patients with the same anatomical localisation and stage may
experience different outcome and treatment morbidity on the same
treatment modality. Despite the development of advanced multi-
disciplinary treatment, survival has only increased modestly.
For the development of new molecular targeted strategies and to
identify patients who are more or less likely to respond to a given
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stherapy, it is important to look into cancer biology and discover
the molecular differences between the anatomical localisations as
well as separating the viral from the smoking and alcohol-induced
cancers.
MicroRNAs (miRNAs) are small 21–22n non-protein-coding
RNAs that regulate mRNA translation and decay. It has become
evident that miRNA plays a significant role in the development
of human cancer, and the miRNA expression pattern is altered
in many types of cancer. Some miRNAs have been characterised as
tumour suppressors (Kozaki et al, 2008) and others as oncogenic
(onco-miRs) (Iorio et al, 2005). MicroRNA patterns are tissue
specific, and in addition, it is often possible to distinguish
carcinomas from normal cells (Visone et al, 2007). MicroRNA
expression profiling for head and neck cancers has been carried
out in different studies, but mostly in cancer cell lines (Tran et al,
2007; Kozaki et al, 2008) or in a few solid tumours (Chang et al,
2008; Wong et al, 2008). Cell lines may not reflect the miRNA
profiles of solid tumours because the particular culture conditions
and clonal selection may radically change miRNA expressions.
In most studies including larger patient materials, only a few
miRNAs have been selected for further investigation (Childs et al,
2009). Furthermore, there have been little consistency in the
published profiles, and the ongoing discovery of new miRNAs
implies the need for new profiles in the search of relevant
diagnostic as well as prognostic biomarkers. A number of miRNAs
have been shown to be upregulated, whereas others were reduced.
MicroRNA-21, which is overexpressed in a number of solid
malignant tumours, was also found in the neoplastic head and
neck cells and has been shown to be a prognostic marker in head
and neck cancer (Childs et al, 2009). The role of HPV on miRNA
expression in head and neck cancers is largely unknown.
In a translational perspective, we examined the global miRNA
expression in a series of consecutive tumours or biopsies obtained
from patients with OSCC, PSCC and controls, respectively. We
report remarkable tissue specificity in both normal and malignant
tissue and that HPV status affects the miRNA expression pattern.
On the basis of these observations, we generated an miRNA-based
classifier that could differentiate between normal and malignant
tissue in the oral cavity. We conclude that progression from
normal epithelium to SCC is followed by changes in miRNA
expression and that miRNA-based signatures may in the future
support diagnosis in head and neck cancer.
MATERIALS AND METHODS
Patient characteristics
The Regional Scientific Ethical Committee (H-C-2008-080)
approved the study. All patients gave informed consent for the
use of tissue harvested at surgery.
In total, 100 patients had biopsies taken for RNA extraction.
Twelve patients were excluded because the tumour cell content was
low or the subsequent histological examination revealed another
diagnosis than SCC. Eighty-eight cancer and control patients
were eligible for analysis. Thirty patients with primary OSCC
(stages I–IV) and 19 patients with primary SCC of oro- and
hypopharynx (stages I–IV) were included. All cancer patients had
histological documented SCC and the tumour grade of differentia-
tion was evaluated according to the WHO criteria by an
experienced pathologist (Eds Barnes, 2005). Tumour stage was
evaluated by the primary study investigator by clinical examina-
tion and CT of the head and neck according to the TNM
classification of Malignant Tumours from International Union
Against Cancer (UICC) (Patel and Shah, 2005). Thirty-nine
patients with non-neoplastic diseases within the head and neck
region were used as controls, of whom 22 had biopsies taken
from the pharynx and 17 had biopsies taken from oral cavity.
Human papilloma virus status was examined for all patients by
three modalities: PCR, p16
INK immunohistochemistry and in situ
hybridisation (ISH).
Tissue collection
Biopsies were harvested during primary surgery and placed
directly in ‘RNA later’. The control group consisted of patients
who obtained surgery for non-neoplastic diseases of the head and
neck in the Department of Otolaryngology, Head and Neck
Surgery, Rigshospitalet, and they were chosen to match the cancer
patient group with regard to age, smoking status and biopsy site.
Control tissue from the tonsils was collected after surgery by
carefully scraping the epithelium from the lymphoid tissue to
avoid prominent infiltration of lymphoid tissue from the samples.
Biopsies were frozen to  801C within 10min.
Microarray analysis
RNA extraction Total RNA was extracted and isolated by
homogenising the frozen samples in Trizol (Invitrogen Corpora-
tion, Carlsbad, CA, USA) using a homogeniser (Tissuelyser; Qiagen
GmbH, BY, Hilden, Germany). Briefly, total RNA was extracted
from tissue lysate by phase separation with BCP (1-bromo-3-
chloropropane) and RNA precipitation with isopropanol. After
washing with alcohol, the RNA was eluted in RNAse free water.
Total RNA concentration of samples was measured using a
Nanodrop ND-1000 Spectrophotometer (NanoDrop Technologies
Inc., Wilmington DE, USA). For microarray analysis, 1000ng of
total RNA was labelled with FlashTag Biotin RNA Labelling Kits
from Genisphere and hybridised to Affymetrix GeneChip miRNA
array according to the manufacturer’s instructions.
Microarray Affymetrix miRNA array chips identify miRNAs in 71
organisms, including small nucleolar RNAs and small Cajal body-
specific RNAs in human beings. Content is derived from Sanger
miRbase miRNA database V11. It is a one-colour array and includes
847 human miRNAs. Four copies of each miRNA probe are
distributed on the array. To minimise batch variation, each batch
was run with equal numbers of OSCC, oral controls, PSCC and
pharyngeal controls. Twenty samples were labelled and hybridised in
each batch. Raw data files were imported into Affymetrix miRNA
QCTool and normalised using the quantiles normalisation and
median Polish summarisation following a background correction
that corrects for the GC content of the each particular probe.
mRNA expression arrays RNA was amplified and labelled using
the Ambion WT Expression Kit (Applied Biosystems, Life Techno-
logies Corporation, Carlsbad, CA, USA) according to the manufac-
turer’s instructions. The labelled samples were hybridised to Human
Gene 1.0 ST GeneChip array (Affymetrix, Santa Clara, CA, USA). The
arrays were washed and stained with phycoerythrin-conjugated
streptavidin using the Affymetrix Fluidics Station 450, and the arrays
were scanned in the Affymetrix GeneArray 2500 scanner to
generate fluorescent images, as described in the Affymetrix
GeneChip protocol. Cell intensity files were generated in the
GeneChip Command Console Software (AGCC) (Affymetrix).
DNA extraction DNA was extracted from the interphase of
the Trizol and precipitated with ethanol. It was dissolved in
lysate buffer and proteinase K, and after another precipitation
with ethanol, the solutions were transferred to spin columns
(NucleoSpin Tissue). After washing, DNA was eluted with water
of 701C.
Quantitative polymerase chain reaction (qPCR) validation was
carried out on miRNAs selected from the miRNA microarray
analysis in 20 samples. cDNA was prepared from 25ng total RNA
using TaqMan MicroRNA Reverse Transcription Kit and TaqMan
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miR-187, miR-31, miR-181b and miR-375. hsa-miR-191 was used for
endogenous control. Quantitative reverse transcription–PCR
(QRT–PCR) reaction was performed using TaqMan Universal PCR
Master Mix No AmpEras UNG, according to the manufacturer’s
instructions, all from Applied Biosystems. Each amplification reaction
was performed in triplicate, and the median value of the three-cycle
threshold was used for further analysis. For calculations of fold
changes, we used the 2
 DCt method (Schmittgen and Livak, 2008).
Human papilloma virus Polymerase chain reaction for HPV
was performed using general primers MY09 and MY11 and
GP5þ/GP6þ (Hsing et al, 1996; Jacobs et al, 1997). Validation of
the DNA quality and the efficacy of the PCR were carried out with
PCR for the housekeeping gene GAPDH.
Immunohistochemistry for p16
INK4A was performed on formalin-
fixed paraffin-embedded tissue slides pre-treated in DAKO PT Link,
incubated with P16 (JC8) antibody, Santa Cruz (Santa Cruz
Biiotechnology Inc., Santa Cruz, CA, USA), and visualised using
DAKO Envision Flexþ system. Slides were evaluated by a patho-
logist as positive, if there was a strong diffuse staining of more than
50% of the tumour cells.
In situ hybridisation was performed on formalin-fixed paraffin-
embedded, 4-mm tissue sections using PathoGene HPV Screening
Probe (Enzo Life Sciences, Lausen, Switzerland) in accordance
with the manufacturer’s instructions. The probe used was a ready
to use cocktail of biotin-labelled HPV6, HPV11, HPV16, HPV18,
HPV31, HPV33 and HPV51.
Positive staining was identified as red nuclear dots. Any
definitive nuclear staining in the tumour cells was considered
positive.
Statistics
Log2 intensities of the 847 human miRNAs were imported into the
Data Analysis software package Qlucore Omnics Explorer 2.1.
Class comparison analysis was performed using Student’s t-test.
Oral cavity and pharynx samples were analysed separately. For
each tissue type, a comparison of cancers vs controls was
performed, and an miRNA was defined as being differentially
expressed between the groups if the P-value was below 0.01 and
the fold change above 1.5. In the PSCC subgroup, we compared
HPV-positive vs -negative cases, and in the OSCC group, we
compared patient samples with and without lymph node
metastases. In these analyses, an miRNA was defined as being
differentially expressed between the groups if the P-value was
below 0.02 and the fold change above 1.5.
Visualisation of differentially expressed miRNAs
The built-in principal component analysis (PCA) tool in Qlucore
Omnics Explorer was used only for visualisation of the grouping of
samples using the genes selected in the class comparison.
Hierarchical clustering was used for the visualisation of selected
differentially expressed miRNAs using average linkage and
Euclidean distance. Hierarchical clustering visualisation of both
samples and variables is carried out using the Euclidean metric
and data, where each variable has been normalised to mean 0 and
variance 1.
Formulation of classifier
The diagnostic classifiers were developed in ‘R’ v. 2.7. For all
classification problems, the training of the classifiers inside the
leave-one-out (LOO) loop consists of two steps: a univariate probe
ranking and selection step, followed by fitting a support vector
machine (SVM) on the sample division using the selected probes
as covariates. All models were optimised by a grid search of
P-value cutoffs (0.01, 5E-02, 1E-02, 5E-03, 1E-03, 5E-04,1E-04) and
the cutoff resulting in a gene signature of optimal performance was
used in the final model. The gene signature in the classifier was
selected with Student’s t-test with a P-value below 5E-04. Model
fitting was carried out by training an SVM with a Gaussian kernel
(Vapnik, 1999).
Test set of classifier
To validate that the classifier can distinguish between OSCC and
normal oral mucosa outside the training setting, a collection of
biopsies from seven patients with OSCC and seven control patients
were harvested independently of the original 48 oral patients in the
study. All control biopsies were taken from the gingival mucosa
from patients operated with tooth extractions at the Department of
Odontology, Copenhagen University. RNA was extracted, labelled
and hybridised to Affymetrix GeneChip miRNA Array with the
same procedure as used for the original samples. Raw data files
from the test set were imported together with the original training
data set into Affymetrix miRNA QCTool and normalised. The 14
samples were used as an independent test set; the classifier was
applied using the signature obtained from the original data set of
48 samples with the criterions described in the classifier.
miRNA target prediction and gene ontology analysis
To predict mRNA changes, based on the observed miRNA profile,
we implemented the method developed by Gallagher et al (2010).
A gene list of predicted mRNA targets for the most significant
aberrations in miRNA expression (more than twofold up or down
between the normal and OSCC) was obtained using miR database
miRDB. Only genes with a target score of more than 80 were
considered and a prediction of which genes should be altered
in view of multiple changes in miRNA concentration were made
according to the method described by Gallagher et al (2010). This
method provides a weighted miRNA inhibitor score (sum of
effects) to the genes predicted as being targets of the regulated
miRs. The overlap between the predicted target genes and the
genes detected as present in the mRNA expression analysis was
examined further. ‘Present genes’ was defined by having an
average intensity above 100, when examining the gene expression
arrays (HuGene ST 1.0; Affymetrix) of the OSCC and controls.
The effect of the up- and downregulated miRNAs was calculated
separately as described by Gallagher et al (2010); however, we
combined the two lists into one by adding the inhibitory effect of
the upregulated miRNAs with the stabilising effect of the down-
regulated miRNAs. We used a cutoff on our weighted inhibitor
score list of ±2, resulting in 497 genes that were used for the
biological function and pathway analyses in Ingenuity system
software.
To assign function to the genes with the highest and lowest
miRNA inhibitor score, biological function analysis was performed
using the Ingenuity system software. This analysis estimates
whether a biological function or pathway is enriched in the gene
list provided compared with a Reference Set of molecules (the
Human Gene 1.0 ST GeneChip array platform (Affymetrix) using a
right-tailed Fisher’s exact test. It gives a significance value as a
measure of the likelihood that the association between a set
of genes in our experiment and a given process or pathway was
due to random chance. A Benjamin–Hochberg (FDR) corrected
P-value of less than 0.05 was regarded as statistically significant.
RESULTS
Patients and tumours
Patient characteristics are summarised in Table 1. The median age
of all patients was 60 years and the age distribution was very
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ssimilar in the OSCC, PSCC and oral cavity control groups, but
slightly lower in the pharyngeal control group. There were a higher
proportion of women in the control groups compared with the
cancer groups, whereas the distribution of smokers vs non-
smokers was similar among the groups. Patients’ tumour and
controls’ biopsy characteristics are listed in Table 2. There were a
higher proportion of higher stages (stage III and IV) in the PSCC
patients than in the OSCC patients, where most patients had stages
I and II. The presence of HPV in the tumours was determined
by PCR and this revealed only one HPV-positive control and
11 positive cancers among 90 samples. Two of the latter were
excluded because the number of tumour cells in two samples was
low. P16
INK4A immunostaining revealed 15 were HPV positive and
by ISH seven were HPV positive. For ensuring to find the ‘true’
HPV caused and clinically relevant HPV-positive patient samples,
all three tests (P16
INK4A immune, ISH and HPV DNA PCR) for
HPV were carried out. Only patients who were tested positive for at
least two of the three parameters were considered HPV positive.
Only eight PSCC and one OSCC fulfilled this criterion and could be
used to evaluate the significance of HPV.
miRNA expression in oral and pharyngeal cancers
To obtain an overview of the differences and similarities of the
miRNA expression among the different cancers and normal tissues
groups, we first visualised the miRNA expression of all samples in
a PCA including all variables. In the uncensored (using all miRs)
PCA plot, the oral control samples and the OSCC samples clustered
into two distinct groups (Figure 1). Furthermore, the PSCC
samples showed a higher degree of heterogeneity and showed
partial overlap with both the OSCC, as expected, and the
pharyngeal controls. This may be due to a higher level of normal
tissue cells in the PSCC biopsies. Overall, the PCA plot showed that
miRNAs are able to separate normal oral mucosa from the
tumours as well as separate normal oral from normal pharyngeal
mucosa.
We subsequently examined oral and pharyngeal tumour
samples, respectively, with the corresponding normal biopsies in
a censored class comparison analysis. Employing a significance
levels of Po0.01 and qo0.06, 114 miRNAs were found to be
differentially expressed between OSCC and oral cavity control
samples (Figure 2). Thirty-six miRNAs were downregulated and 78
upregulated. The most significant aberration was a 418-fold
downregulation of miR-375 in oral cancers. The highest upregu-
lated miRNA was miR-31, which was increased 6.9-fold. The 25
most highly differentially expressed miRNAs are listed in Table 3.
As miRNAs could be implicated in tumour progression and
metastasis, we also compared miRNAs in OSCC from different
stages and with or without lymph node metastasis. Tumours
with different staging did not reveal major differences in the
miRNA expression, so we subsequently grouped all tumours with
metastasis and analysed them against the remaining tumours.
Eighteen miRNAs were differentially expressed between OSCC
with lymph node metastases and OSCC without lymph node
metastases at a significance level of Po0.02 and a false discovery
rate (FDR) of qo0.6 (Figure 3). However, the fold changes were
small and ranged from  3 to 1.5 and none of the identified
miRNAs were unique to any of the categories.
As shown in the PCA plot, OSCC and PSCC samples were more
similar to each other compared with the normal epithelia
(Figure 1). In a direct comparison of oral and pharyngeal tumours
(Figure 5), 46 miRNAs were found to be differentially expressed
(Po0.01 and an FDR qo0.13). Twenty-one miRNAs were
upregulated and 25 miRNAs were downregulated. None of the
miRNAs were exclusive to the groups and the fold changes were
moderate. Two samples did not cluster correctly according to their
anatomical subsite, of which one was in the soft palate just on the
border of oral cavity and pharynx and one sample was an oral
HPV-positive SCC. Comparing PSCC with normal pharyngeal
epithelium revealed only 38 differentially expressed miRNAs
(Po0.01, qo0.2) (Supplementary Figure 1). Twenty of these were
also perturbed in the OSCC (Supplementary Figure 2). Within the
PSCC samples, we moreover compared the HPV-positive and -
negative cancers. However, when the samples were selected based
on P16
INK4A immune or ISH staining alone, there was no difference
between the groups, but a clear separation was seen with HPV
PCR. However, if two of the three criteria were positive, as
described above, the optimal separation between the HPV-positive
Table 1 Patient characteristics
OSCC
patients
Oral cavity
control
patients
PSCC
patients
Pharyngeal
control
patients Total
Number of patients 30 17 19 22 88
Gender
Female 15 10 6 16 47
Male 15 7 14 6 42
Age
Median 61 62 61 36 60
Smoking status
Never smoked 8 6 8 10 32
Former smoker 2 1 2 2 7
Current smoker 18 8 9 10 45
N D 220 4
Abbreviations: ND¼not determined; OSCC¼oral squamous cell carcinoma;
PSCC¼pharyngeal squamous cell carcinoma.
Table 2 Tumour and normal tissue biopsy characteristics
OSCC
Oral cavity
controls PSCC
Pharyngeal
controls Total
Primary tumour location
Tongue 15 8 23
Bucca 2 8 10
Floor of mouth 7 1 8
Gingiva 5 5
Other oral cavity 1 1
Tonsil 5 14 19
Base of tongue 10 1 9
Other pharynx 4 7 11
Stage
I1 2 1 1 3
II 8 4 12
III 4 7 11
IVa and IVb 6 5 11
Grade
Well differentiated 5 2 7
Intermediate
differentiated
12 7 19
Poorly differentiated 13 10 23
p16 positive 3 0 10 0 13
In situ hybridisation
positive
10 607
PCR HPV positive 3 0 6 1 9
HPV positive by two
parameters
10 809
Abbreviations: HPV¼human papilloma virus; ND¼not determined; OSCC¼oral
squamous cell carcinoma; PCR¼polymerase chain reaction; PSCC¼pharyngeal
squamous cell carcinoma.
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sand -negative groups was found (see Figure 4), and a number of
miRNAs turned out to be differentially expressed (Table 4). The
most upregulated miRNA was miR-363 and the most down-
regulated miRNAs were miR127-3p and miR-379, which exhibited
fold changes of 1.6,  2.5 and  2, respectively (Po0.02, qo0.5).
Although OSCC and PSCC were partially similar (Figure 1),
we observed that fewer miRNAs (114 vs 38) differed among
pharyngeal cancers and the normal pharyngeal epithelium,
indicating that miRNAs were different in the two epithelial linings.
Consequently, we compared the miRNA composition in the two
anatomical locations (Figure 5). The signature differed and 127
miRNAs distinguished the two epithelia (Po0.01, qo0.06).
Fifty-six were upregulated and 71 were downregulated, respec-
tively, in the normal oral vs pharyngeal epithelium. There was
almost a 10-fold less miR-150 and a fivefold more miR-1224 and
miR-375 expression in the oral epithelium. This suggests that
miRNAs may be important for maintaining distinct phenotypes of
oral epithelium in the oral cavity and pharynx. The trend towards
different expression profiles in patients with and without lymph
node metastases was not observed in PSCC samples (as opposed to
the OSCC samples). In addition, no differences in the miRNA
expression were observed when comparing histological differen-
tiation, stage or smoking status.
Finally, five miRNAs and 20 samples were selected for validation
by qPCR. MicroRNA-125b and miR-181b were used only for oral
cavity samples comparing oral cavity cancer samples (n¼5) with
oral cavity control samples (n¼5). MicroRNA-375, miR-187 and
miR-31 were used for qPCR in comparing all four groups (OSCC
(n¼5), oral cavity controls (n¼5), PSCC (n¼5) and pharyngeal
controls (n¼5)). The results of the qPCR validation are shown in
Supplementary Figure 3. In all cases, qPCR results confirmed the
array data.
Generation of a diagnostic classifier for oral cancer
As the analysis of differentially expressed miRNAs provided a
putative signature for oral carcinogenesis, we generated a classifier
that could differentiate between normal epithelium and malignant
lesions. The classifier was based on the SVM algorithm developed
in our R script. We compared the accuracy of the prediction by
using the different classification methods implemented in BRB-
Array tools. We selected 61 miRNAs to discriminate between the
normal oral biopsies and OSCCs. Basically all the employed
algorithms provided accurate predictions. The cross-validation
misclassification rate using the LOOCV procedure was 0% for all
the tested P-value cutoff. The composition of the classifier is
shown in Supplementary Table 1. The diagnostic signature was
moreover tested on an independent validation material consisting
of seven OSCC biopsies and seven biopsies with normal
epithelium. Collection of biopsies for the test set as well as the
RNA isolation, hybridisation to array and all analyses were
performed completely independent of the training set. In the test
set, one normal sample was falsely classified as cancer, resulting in
an accuracy of 93% (13 out of 14) and a sensitivity and specificity,
respectively, of 100% (7 out of 7) and 86% (6 out of 7). The
predicted probability of the new samples belonging to the class of
cancer/normal epithelium is shown in Supplementary Table 2.
We conclude that miRNAs signatures are efficient in the
diagnosis of oral cancer.
Gene expression in oral cancer
One thousand eight hundred eighty-three genes were differentially
expressed between oral cancer and oral controls with an adjusted
P-value (FDR qo0.05, Po0.007, variance 0.07). The most
significant aberrations were an 87-fold upregulation of POSTN
(periostin, osteoblast-specific factor), 83-fold upregulation
of MMP1 (matrix metallopeptidase 1 (interstitial collagenase))
and a 56-fold downregulation of TMPRSS11B (transmembrane
protease, serine 11B), as well as a 27-fold downregulation of KRT4
(keratin4). The 20 most up- and downregulated genes are listed in
Supplementary Table 3 and a heatmap of differentially expressed
genes between the two groups are shown in Supplementary
Figure 4. The significant differentially expressed genes (Po0.007,
qo0.05, fold change 42/ 2) were imported into the Ingenuity
Systems Pathway Analysis and a gene set enrichment analysis (Core
IPA) was made to define pathways or biological functions, which
have a likelihood of being regulated in the oral cavity cancers.
Summary of core pathway analysis revealed that the following
molecular and cellular functions were most significantly enriched in
the gene list: cellular movement, cell morphology, cellular growth
and proliferation, cell-to-cell signalling and interaction together
with cellular development. One of the top canonical pathways was,
as in the miRNA predicted pathways, the TGFb signalling. On the
basis of the biological functions that were enriched in the regulated
gene list, the software proposes the diseases where these biological
functions may be affected. The proposed diseases were as follows:
connective tissue disorder, genetic disorder and cancer. Supple-
mentary Tables 5–10 illustrate the summary of the analysis.
miRNA target prediction and gene ontology analysis
From the miRNA that changed more than fivefold up or down
between OSCC and oral controls, we found 452 predicted target
genes, which had a combined weighted inhibitor score of more
than 2/ 2. Fifty genes with the highest and lowest combined score
as well as their matching fold changes identified in the gene
expressions analysis are shown in Supplementary Table 4. As
shown in the table, no systematic correlation between the weighted
combined score and the matching fold changes in the gene
expressions from the same samples could be found. The 452 genes
with a combined score of 2/ 2 were used for the core analysis of
the functions of the predicted target genes in Ingenuity Systems
Pathway Analysis. The analysis of predicted target genes displayed
distinct molecular and cellular functions. In summary, cell cycle,
cell death, cellular growth and proliferation, as well as post-
translational modification were the most prominent features.
OSCC
1 (7%)
3 (4%)
2 (6%)
Oral control
PSCC
Pharyngeal control
Figure 1 Principal component analysis of all four patient groups using all
847 miRs measured on the microarray. Oral squamous cell carcinoma
(purple), oral cavity controls (gold), PSCC (off-white) and pharyngeal
controls (black). The oral cavity controls and the OSCC samples cluster
into two distinct groups. The PSCC samples showed a higher degree of
heterogeneity and shows partial overlap with both the OSCC and the
pharyngeal controls. The PCA analysis and visualisation was performed
using the Qlucore Gene Expression Explorer (www.qlucore.com).
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and IGF-1 signalling. From these biological functions, a suggestion
of disease was made and satisfactorily the number one predicted
disease was cancer. Supplementary Tables 11–16 illustrate the
summary of the analysis.
DISCUSSION
Even though advances in diagnostic tools and treatments have
been achieved over the past three decades, the mortality of head
and neck cancer patients is still high and the offered treatment
modalities are still associated with major adverse effects with
considerable impact in the quality of life (Corry et al, 2010).
HNSCC comprises a group of diverse heterogeneous cancers that
develop from many different anatomical sites and are associated
with different risk factors related to both behaviour and genetic
background (Marcu and Yeoh, 2009). Clinical features and
prognosis are likewise very different, and it would be of great
importance to obtain site-specific miRNA signatures to verify
origin of the tumour and prognostic values. For example, HPV
status greatly influences the clinical features and prognosis (Lajer
and Buchwald, 2010). This emphasises the importance of using
larger patient material for profiling analysis as cell lines may
not fully reflect the miRNA profiles of solid tumours and
may be inadequate to illustrate the diversity among the different
HNSCC.
Barker et al (2009) used miRNA expression profiles to identify
unknown primary lesions in the head and neck region for three
distinct subsites, that is, the tonsils, base of tongue and post-nasal
space (Barker et al, 2009). However, in another study on formalin-
fixed paraffin-embedded specimens, Hui et al (2010) did not see
any difference in the expression profiles of three subsites, that is,
the hypopharynx, the oropharynx and the larynx. This underlines
the importance of further analysis, legalising this study.
There is a considerable variation in the miRNA profiles across
the various miRNA profile studies of head and neck cancer.
Differences may reflect both technically issues and differences in
stage, grade and sampling from multiple anatomical sites as well as
the use of cell lines.
We performed a prospective translational and multidisciplinary
study comprising a large and clinically well-defined patient
material, which allowed us to generate site-specific miRNA
expression profiles from oral cavity and pharyngeal cancers, as
well as determine the influence of HPV on miRNA expression
profile in head and neck cancers.
OSCC
Oral control
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Figure 2 Visualisation of 114 differentially expressed miRs in OSCC and oral cavity controls (Po0.01, qo0.06) p. (A) Heatmap: Two distinct groups
were observed. OSCC (purple) and oral cavity controls (gold). (B) PCA plot: OSCC (purple) vs oral cavity controls (gold). The heatmap and PCA
visualisation was performed using the Qlucore Gene Expression Explorer (www.qlucore.com).
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profiles and benign and malignant samples separated clearly even
in the uncensored PCA plots. Homogeneity was particularly
striking among the OSCC and oral cavity control samples, whereas
the PSCC and pharyngeal control samples were more diverse.
One of the reasons for this may be a higher contamination of
non-tumour cells in the biopsies from the PSCC patients, which are
much more difficult to examine and perform biopsies from,
compared with oral cavity cancers, which normally present
themselves as a clear visible tumour easy to distinguish from
surrounding structures. The difference between cancer samples
and controls was also less pronounced in the pharynx. Many of the
miRNAs lost in oral cancers and highly expressed in oral controls
were more highly expressed in the pharyngeal cancers and only
slightly higher expressed in the pharyngeal controls, indicating a
higher resemblance in miRNA profile of pharyngeal epithelium
with cancer. We also noted a marked difference in the miRNA
expression between the controls from the oral cavity and pharynx.
This may be related to the higher cell turnover of pharyngeal
mucosa than oral mucosa (Squier et al, 1976). In addition, the
mucosa from the oral cavity has an ectodermic origin, whereas the
pharyngeal mucosa is of endodermic origin. The considerable
difference between the oral cavity and pharynx in the expression
profiles of both malignant and control tissue emphasises the
importance of examining the different anatomical sites separately.
In this study, we found a considerable number of differentially
regulated miRNA in the cancer tissue compared with the controls.
Although a number of the former has been identified in other
profile studies, a large fraction has not been described in head
and neck cancer before. In the comprehensive profile study of
51 tumour samples of the oral cavity, pharynx and larynx by
Hui et al (2010), only 10 miRNAs (miR-93, miR-25, miR-155,
miR-21, miR-let7i, miR-223, miR-99a, miR100, miR-125b,
miR-375) from a total of 322 examined miRNAs were identical
to the ones found in this study.
The most differentially regulated miRNAs in this study was miR-
375, which was highly expressed in oral controls and almost absent
in the OSCCs, but the difference between cancer and control
was much less pronounced in the pharynx. This finding is in
accordance with a previous report (Avissar et al, 2009) showing
that miR-375 expression was higher in tumours of pharyngeal and
Table 3 OSCC compared with oral cavity controls
Probeset name P-value
q-value
(FDR)
Fold change
SCC/control
hsa-miR-375_st 1.35E-16 3.49E-14  20
hsa-miR-1224-5p_st 4.48E-18 3.47E-15  11.1
hsa-miR-617_st 8.22E-17 3.19E-14  8.3
hsa-miR-99a_st 1.13E-12 2.18E-10  5.3
hsa-miR-125b_st 4.8E-07 0.0000233  2.3
hsa-miR-378_st 2.09E-06 0.0000676  2.1
hsa-miR-27b_st 1.14E-06 0.0000422  2
hsa-miR-125b-2-star_st 4.14E-06 0.000107  2
hsa-miR-21-star_st 3.14E-07 0.0000162 2
hsa-miR-345_st 6.68E-06 0.000157 2.1
hsa-miR-106b-star_st 2.58E-06 0.0000768 2.2
hsa-miR-132_st 6.91E-07 0.0000297 2.3
hsa-miR-27a-star_st 5.35E-10 5.93E-08 2.4
hsa-miR-181b_st 8.05E-08 0.00000567 2.4
hsa-miR-181a_st 1.54E-07 0.00000918 2.4
hsa-miR-424-star_st 7.77E-10 7.53E-08 2.9
hsa-miR-155_st 8.41E-07 0.0000326 2.9
hsa-miR-146a_st 7.57E-07 0.0000309 3
hsa-miR-146b-5p_st 1.26E-07 0.00000816 3.1
hsa-miR-1246_st 4.53E-08 0.00000351 3.6
hsa-miR-187_st 2.02E-09 0.000000174 3.8
hsa-miR-503_st 1.81E-12 2.81E-10 4.2
hsa-miR-223_st 2.25E-06 0.0000698 4.26
hsa-miR-21_st 9.2E-11 1.19E-08 5.6
hsa-miR-31_st 1.79E-06 0.000063 6.85
Abbreviations: FDR¼false discovery rate; miRNA¼microRNA; OSCC¼oral
squamous cell carcinoma.
Top 25 significant differentially expressed miRNAs with fold change of more than 2.
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Figure 3 Visualisation of 18 differentially expressed miRs between the OSCC samples with lymph node metastases (yellow) and OSCC samples without
lymph node metastasis (purple). Po0.02, qo0.6. (A) Heat map and (B) PCA plot.
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slaryngeal origin compared with oral tumours. MicroRNA-375 is
involved in the glucose regulation of insulin gene expression and
cell growth, decreasing the cell’s sensitivity to insulin. Malignant
cells, and especially those originating from head and neck cancers,
have a high glucose uptake, so an upregulation of glucose
transporters is in accordance with a high sensitivity to insulin
that is not blocked by miR-375. In accordance with this, four
glucose transporters were upregulated in our gene arrays (SLC2A1,
SLC2A3, SLC2A9 and SLC2A14).
MicroRNA-31 was significantly upregulated in the OSCC
samples. This has also been shown in OSCC tissue, saliva
and blood in other studies (Liu et al, 2010), as well as in
cervical cancer, lung cancer and colorectal cancers (Muralidhar
et al, 2007).
MicroRNA-187 was upregulated in both OSCC and PSCC, and
has also been found to be upregulated in other malignant tumours,
for example, thyroid cancer (Nikiforova et al, 2008). Previously,
identification of miR-181b, miR-21 and miR-345 in oral leuko-
plakia has indicated that these miRNAs may be part of progression
to malignancy (Cervigne et al, 2009). All these miRNA were
upregulated in the OSCC samples. MicroRNA-181b was also found
to be more highly expressed in patients with lymph node
metastases from oral cavity cancer. These observations strongly
support that these miRNAs may have diagnostic as well as
prognostic value. In addition, we found a significant down-
regulation of miR-125b and miR-100. MicroRNA-125b is fre-
quently downregulated in a number of malignancies, including
breast and prostate cancers (Shi et al, 2008; O’Day and Lal, 2010).
In breast cancer, miR-125b is downregulated and it may function
as a tumour suppressor. When over expressed in breast cancer cell
lines, miR-125b suppresses HER2 and HER3 mRNA and protein
levels leading to a reduction in anchorage-dependent growth, cell
motility and invasiveness (O’Day and Lal, 2010). Furthermore, this
miRNA is reported to target p53 and several of the upstream
regulators (Zhang et al, 2009).
Several genetic aberrations are characteristic of OSCC, with
amplification and deletions of chromosomal band 11q13 and loss
of distal 11q being among the most prevalent. MicroRNA-100 and
miR-125 are closely located at the distal part of chromosome 11q.
Loss of heterozygosity has been reported in over 60% of HNSCC at
11q and several oncogenes and tumour suppressor genes are
located at chromosome 11 (Scully et al, 2000). It is hypothesised
that the expression of miRNAs mapping to 11q is altered in OSCC
because of loss or amplification of chromosomal material, and that
this contributes to the development and progression of OSCC.
In OSCC tumours and cell lines, it was found that miR-125b and
miR-100 expression were downregulated and that transfecting cells
with exogenous miR-125b and miR-100 significantly reduced cell
proliferation and modified the expression of target and non-target
genes, including some that are overexpressed in radio-resistant
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Figure 4 Visualisation of differentially expressed miRs in HPV-positive compared with HPV-negative PSCC. (A) Heat map: HPV-positive PSCC (purple)
and HPV-negative PSCC (black). (B) PCA plot: HPV-positive PSCC (purple) vs HPV-negative PSCC (black). The miRs were selected with Student’s t-test
with Po0.02, qo0.36 and a fold change 41.5.
Table 4 List of 21 differentially expressed miRNAs with a fold change of
more than 1.5 in HPV-positive PSCC compared with HPV-negative PSCC
(Po0.02, qo0.5)
Probeset name P-value q-value Fold change
hsa-miR-127-3p_st 0.01089 0.49  2.5
hsa-miR-379_st 0.00077 0.228  2.4
hsa-miR-125a-5p_st 0.00976 0.49  2.1
hsa-miR-432_st 0.01914 0.49  1.9
hsa-miR-143_st 0.00262 0.303  1.9
hsa-miR-145_st 0.00144 0.228  1.9
hsa-miR-409-5p_st 0.01931 0.49  1.9
hsa-miR-433_st 0.01831 0.49  1.9
hsa-miR-381_st 0.00128 0.228  1.9
hsa-miR-199a-3p_st 0.01379 0.49  1.8
hsa-miR-199b-3p_st 0.01523 0.49  1.8
hsa-miR-26b_st 0.0092 0.49  1.8
hsa-miR-199b-5p_st 0.01441 0.49  1.7
hsa-miR-143-star_st 0.00168 0.228  1.7
hsa-miR-1201_st 0.00927 0.49  1.7
hsa-miR-126_st 0.00038 0.228  1.7
hsa-miR-409-3p_st 0.0156 0.49  1.6
hsa-miR-101_st 0.00698 0.49  1.6
hsa-miR-517a_st 0.01038 0.49  1.5
hsa-miR-195-star_st 0.01467 0.49 1.5
hsa-miR-363_st 0.01581 0.49 1.6
Abbreviations: HPV¼human papilloma virus; miRNA¼microRNA; PSCC¼
pharyngeal squamous cell carcinoma.
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control sample was misclassified as a cancer sample in the test
set of the classifier, it showed high levels of both miR-125b and
miR-100.
Despite the fact that no direct correlation could be seen between
the miRNA expression and the gene expression, the analysis of
predicted target genes of the most significantly changed miRNAs
pointed at a series of target mRNA encoding proteins involved
in cancer. There was no consistent and significant change in the
mRNA expression of genes that contained onco-miR or tumour
suppressor miR target sites, indicating that target protein
translation rather than mRNA cleavage may be the prominent
OSCC
Oral control
PSCC
Pharyngeal control
1 (49%)
3 (7%)
2 (10%)
1 (57%)
3 (15%)
2 (22%)
AB
CD
Figure 5 Visualisation of differentially expressed miRs between oral cavity samples and pharyngeal samples. (A and B) Control samples. (A) Heatmap:
Oral cavity samples (gold) and pharyngeal samples (black). (B) PCA plot: Oral cavity samples (gold) and pharyngeal samples (black). (Subset of variables
Po0.001, qo0.01.) (C and D) SCC samples: (C) Heatmap: PSCC samples (off-white) and OSCC samples (purple). (D) PCA plot: PSCC samples
(off-white) and OSCC samples (purple) (Po0.01, qo0.13).
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sfeature. In addition, other studies, recording global analysis of the
relationship between miRNA and the proteome, found that single
miRNA expression alterations only had modest impact on
individual protein expression (Baek et al, 2008; Selbach et al,
2008). Furthermore, Gallagher et al (2010) suggested that the
collective changes in many miRNAs may be the most biologically
interesting parameter to consider and they hypothesised that it is
most likely that miRNAs work cooperatively in vivo and
physiological regulation of a single protein by a single miRNA
may be a rather rare occurrence. In addition, evidence of cleavage
of mRNA as a result of miRNA binding originates from cell line
studies, where a large change in one miRNA is created by
transfecting or by knock down. This may be far from the
conditions in vivo. In the study from Gallagher et al (2010), they
did not find any correlation between the miRNA expression and
the genome expression either.
Even though there was no correlation with miRNA profile and
stage or grade, a distinct miRNA expression pattern was associated
with lymph node metastasis in the oral cavity cancer group.
MicroRNA-181b was upregulated and miR-942 and miR-181c*
were downregulated, respectively. The number of patients with
lymph node metastasis in this study is too low to make a clear
signature and the changes were moderate as described. Additional
investigation in a prognostic study is obviously needed. Biomar-
kers that predict primary tumours with metastatic potential are of
clinical importance, as spread of tumour cells to the regional
lymph nodes in the neck is the most important independent
prognostic factor in head and neck cancer patients. The presence
of lymph node metastases in HNSCC patients at the time of
diagnosis reduces the survival to 50% compared with patients
without nodal involvement (N0). In addition, nodal metastasis
occurs in 20–50% of patients with clinically N0 head and neck
cancer. Treating the neck with either surgical neck dissection or
radiotherapy is accompanied with significant side effects, and the
treatment strategy of cervical lymph nodes is still under debate
(von Buchwald et al, 2002).
Human papilloma virus-positive HNSCC appears to be different
from HPV-negative HNSCC in both molecular and clinical features
(Lajer and Buchwald, 2010). In general, it is recommended that at
least two standardised and recognised methods should be used to
confirm the diagnosis of clinically relevant HPV-positive HNSCC.
This is underscored in this project as a clear separation in the PCA
plots and heatmaps could only be achieved when at least two out of
three positive criteria were met. Human papilloma virus status
clearly has an influence on the miRNA expression profiles.
A number of miRNAs were perturbed in the HPV-positive
pharyngeal SCC samples compared with the HPV-negative
pharyngeal SCC. The observed fold changes were as described
modest and the FDR relatively high. This is at least partly due to a
prominent infiltration of normal tissue in the HPV-negative PSCC
and low number of HPV-positive samples. MicroRNA-145,
miR-125a and miR-126, which are reduced in the HPV-positive
PSCC, are also downregulated in cervical cancer tissue (Wang et al,
2008) and miR-126 has been suggested to function as a tumour
suppressor in gastric and colorectal cancers (Feng et al, 2010;
Li et al, 2010). MicroRNA-145 has been shown to be crucial for the
gut development and epithelial maturation (Zeng et al, 2009).
Notably, a recent study showed that miR-125a-5p can inhibit
migration and invasion of lung cancer cells (Wang et al, 2009) and
transfection of miR-125a-5p in an intestinal epithelial cell line
decreased growth rate and transepithelial resistance of the cells
(Dalmasso et al, 2010).
MiR-363 was elevated in the HPV-positive PSCC samples. This is
in concordance with a most recent study, in which HPV-positive
head and neck cancer cell lines showed a considerable upregula-
tion of miR-363 and an siRNA knockdown of HPV16 E6 was
accompanied by a reduction of miR-363 levels (Wald et al, 2010).
MicroRNA-127-3p and miR-379 were both downregulated among
the HPV-positive PSCC. These two miRNAs have been found to be
differentially expressed in smokers vs non-smokers in patients
with malignant mesothelioma and this may reflect the limited
number of smokers in the HPV-positive PSCC group. The present
material comprised only had five tonsillar SCC. To make a clear
HPV miRNA classifier, it probably needs to include micro-
dissected formalin-fixed paraffin-embedded tonsillar specimens
to ensure a high proportion of HPV-positive samples and even
tissue specificity.
We finally examined whether or not the distinct miRNA
signatures could provide a solid basis for diagnostic classification
between normal epithelium and malignant lesions in the oral
cavity. A robust classifier was generated for oral cavity cancer, with
an accuracy of 93% in the test samples. The test sample that failed
was obtained from a patient who had clear inflammation in the
area where the biopsy was taken. This sample clearly clustered with
cancer samples and it may indicate that there are some similarities
in the miRNA profiles between cancer and inflammation. Even
though the test set was small, the classifier seemed robust, but
needs to be confirmed in a larger validation study. A validation
study should preferably also include inflamed tissue, which seems
to have a degree of resemblance with malignant tissue as indicated
above.
In conclusion, we found significant differences in miRNA
expression profiles of malignant and benign tissue samples as
well as remarkable site-specific differences. In addition, the
presence of lymph node metastasis at the time of diagnosis in
oral SCC seems to influence the miRNA expression. Human
papilloma virus infection in pharyngeal SCC shows a distinct
miRNA expression profile, but needs to be further elucidated in
a specific tonsillar SCC material.
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